Alterity Therapeutics Ltd. (ATHE) intrinsic value & 10-year financials
Alterity Therapeutics Ltd. (ATHE) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- 18.8%
- ROIC (10-yr avg)
- -59.8%
- Free cash flow (FY2025)
- —
ATHE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -AUD 12.1M | -AUD 0.19 | — | — | -43.2% |
| FY2024 | — | -AUD 19.1M | -AUD 0.52 | -AUD 12.6M | — | -104.5% |
| FY2023 | — | -AUD 13.8M | -AUD 0.57 | -AUD 20.0M | — | -47.4% |
| FY2022 | — | -AUD 12.8M | -AUD 0.53 | -AUD 12.4M | — | -39.0% |
| FY2021 | — | -AUD 15.3M | -AUD 0.90 | -AUD 17.3M | — | -81.4% |
| FY2020 | — | -AUD 13.5M | -AUD 1.50 | -AUD 9.4M | — | -113.5% |
| FY2019 | — | -AUD 12.3M | -AUD 2.00 | -AUD 14.0M | — | -75.6% |
| FY2018 | AUD 201.2K | -AUD 8.3M | — | -AUD 6.3M | — | -41.6% |
| FY2017 | AUD 132.4K | -AUD 7.5M | — | -AUD 5.9M | — | -27.4% |
| FY2016 | AUD 142.7K | -AUD 7.7M | — | -AUD 7.4M | — | -24.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in AUD.
Executive summary
ALTERITY THERAPEUTICS LTD revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ALTERITY THERAPEUTICS LTD has historically struggled to out-earn its cost of capital, averaging just -59.8% ROIC.
ALTERITY THERAPEUTICS LTD has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ALTERITY THERAPEUTICS LTD is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-6.31 per share.